4:23 PM
 | 
Oct 11, 2017
 |  BC Extra  |  Company News

Lupin gets newly approved drug in Symbiomix deal

Editor's Note: This article was updated on Oct 12, 2017 at 8:21 AM PDT

Lupin Ltd. (NSE:LUPIN; BSE:500257) said it acquired anti-infectives company Symbiomix Therapeutics LLC (Newark, N.J.). The deal gives the Indian pharma rights to Solosec secnidazole, which FDA approved last month to treat bacterial vaginosis.

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >